Core Insights - Vivos Inc. is preparing to open two new production facilities to enhance its RadioGel Radionuclide Therapy production capabilities [1] Group 1: Production Facilities - The company has been assessing alternate facilities for the past two years due to risks associated with relying on a single production site [2] - Vivos aims to have one domestic production facility and one international production facility operational by 2026, which will produce Y-90 phosphate particles mixed with sterile hydrogel for patient doses [2] - A contract has been signed for production space at the Applied Process Engineering Laboratory (APEL) in Richland, Washington, with manufacturing equipment ordered and installation underway [3] Group 2: International Expansion - The company is in discussions with radiopharmaceutical contract manufacturers in India to establish an international production facility, expected to be operational by the end of 2026 [4] - The international production footprint is anticipated to reduce shipping costs and logistical complexity, thereby expanding access to international markets for both RadioGel and IsoPet therapies [4] Group 3: Future Development - APEL will serve as a cornerstone for the company's automated production development, supporting higher production volumes and long-term expansion [3]

Core Viewpoint - The gross profit margin of Taiwan Semiconductor is expected to decline annually over the next several years due to the diversification of its manufacturing outside of Taiwan [1] Group 1 - Taiwan Semiconductor is diversifying its manufacturing base beyond Taiwan, which will lead to increased production costs in the coming years [1]